In the future studies, it will be necessary to address the balance between methytransferase EZH2 and demethylases JMJD3/UTX in PCa and CRPC cell lines, and, importantly, in the primary patients PCa samples, that can warrant H3K27 methylation pathway as a therapeutic target for CRPC treatment. Here, KDM6B is linked to posterior cortical atrophy.